Cardio Diagnostics Holdings, Inc.

• locale

  United States

• market

  STOCKS

• industry

  Biotechnology

• website

  cardiodiagnosticsinc.com

• ipo date

  Jan 14, 2022

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

*Estimate based on analyst consensus